• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文学位 >Immunotherapeutic options for the treatment of neuroblastoma: An analysis of natural killer cell and gamma delta T cell based immunotherapy.
【24h】

Immunotherapeutic options for the treatment of neuroblastoma: An analysis of natural killer cell and gamma delta T cell based immunotherapy.

机译：用于治疗神经母细胞瘤的免疫治疗选择：基于自然杀伤细胞和伽马三角洲T细胞的免疫疗法分析。

获取原文
获取原文并翻译 | 示例
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Neuroblastoma is an aggressive solid tumor that develops from immature cells of the nervous system and is almost exclusively diagnosed in infants and young children. Over the past decade a multitude of immune based therapies have been explored as therapeutic candidates for patients with neuroblastoma. The anti-GD2 monoclonal antibody, 3F8, and more recently, natural kill (NK) cell based therapies have been accepted as hopeful therapeutic options for patients with Neuroblastoma. These options however have many drawbacks including dose limiting pain, the development of tolerance, reliance on MHC mismatch and possible reliance on the invariant NK (iNK) cells population.;gammadelta T cells, a subpopulation of T cells composed of a T cell receptor (TCR) with a gamma and a delta chain instead of an alpha and a beta; chain, have been shown to recruit a more robust immune response then both 3F8 and NK cells through their activation of antigen presenting cells (APCs) and non-reliance on MHC mismatch. gammadelta T cells are also able to recruit NK cells as well as other cytotoxic lymphocytes. For these reasons, it is believed that gammadelta T cell based treatment alone or in combination with an anti-GD2 monoclonal antibody may have a greater efficacy than either NK cells or an anti-GD2 monoclonal antibody alone. The intent of this thesis is to explore and evaluate the current state of gammadelta T cell based immunotherapy against the backdrop of NK cell based immunotherapy for neuroblastoma.
机译：神经母细胞瘤是一种侵袭性实体瘤，由神经系统的未成熟细胞发展而来，几乎仅在婴儿和幼儿中被诊断出。在过去的十年中，已经探索了多种基于免疫的疗法作为神经母细胞瘤患者的治疗候选药物。抗GD2单克隆抗体，3F8和最近基于自然杀伤（NK）细胞的疗法已被视为神经母细胞瘤患者的希望疗法。然而，这些选择有许多缺点，包括剂量限制性疼痛，耐受性的发展，对MHC错配的依赖以及可能对不变的NK（iNK）细胞群体的依赖。;γT细胞，由T细胞受体组成的T细胞亚群（ （TCR），带有一个γ和一个δ链，而不是一个alpha和一个beta；链显示，通过激活抗原呈递细胞（APC）和不依赖MHC错配，可以招募比3F8和NK细胞更强壮的免疫反应。 γT细胞也能够募集NK细胞以及其他细胞毒性淋巴细胞。由于这些原因，据信与单独的NK细胞或单独的抗GD2单克隆抗体相比，单独或与抗GD2单克隆抗体组合的基于γT细胞的治疗可能具有更大的功效。本论文的目的是在基于NK细胞的神经母细胞瘤免疫治疗的背景下，探索和评估基于γT细胞的免疫治疗的现状。

著录项

  • 作者

    Bixby, Catherine E.;

  • 作者单位

    Boston University.;

  • 授予单位 Boston University.;
  • 学科 Immunology.;Medicine.;Oncology.
  • 学位 M.S.
  • 年度 2014
  • 页码 79 p.
  • 总页数 79
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-17 11:53:47

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号